The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Journal article

Open access

Peer reviewed

Kate C. Tatham, Manu Shankar-Hari and Yaseen M. Arabi

Intensive care medicine, Vol.47(11), pp.1315-1318

01/11/2021

PMID: 34617150

Abstract

Critical Care Medicine

General & Internal Medicine

Life Sciences & Biomedicine

Science & Technology

url

https://doi.org/10.1007/s00134-021-06540-wView

Published (Version of record) Open

1 Record Views

Title: The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
Creators - without role: Kate C. Tatham - Royal Marsden NHS Foundation Trust
Manu Shankar-Hari - St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, ICU Support Off, 1st Floor,East Wing, London SE1 7EH, England
Yaseen M. Arabi - King Saud bin Abdulaziz University for Health Sciences
Publication Details: Intensive care medicine, Vol.47(11), pp.1315-1318
Publisher: Springer Nature
Number of pages: 4
Grant note: CS-2016-16-011 / National Institute for Health Research Clinician Scientist Award
Identifiers: 9921539108331
Academic Unit: King Abdulaziz University; King Saud Bin Abdulaziz University for Health Sciences
Language: English
Resource Type: Journal article